The early termination of the Phase III COMPASS outcomes study of Johnson & Johnson/Bayer AG's Factor Xa inhibitor Xarelto opens the door for a new arterial disease indication that could mean a new chronic use and a competitive advantage over other novel anticoagulants, if the company succeeds in getting a label change.
Janssen Pharmaceuticals Inc. and partner Bayer, which markets the drug outside the US, announced Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?